256 related articles for article (PubMed ID: 10477391)
1. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice.
Lasek W; Golab J; Maśliński W; Switaj T; Bałkowiec EZ; Stokłosa T; Giermasz A; Malejczyk M; Jakóbisiak M
Eur Cytokine Netw; 1999 Sep; 10(3):345-56. PubMed ID: 10477391
[TBL] [Abstract][Full Text] [Related]
2. Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene.
Cao X; Wang Q; Ju DW; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):191-200. PubMed ID: 10464706
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
4. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
[TBL] [Abstract][Full Text] [Related]
5. IL-12 or IL-15, unlike IL-2, does not interact with histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells.
Kozar K; Kaminski R; Giermasz A; Basak G; Zagozdzon R; Rybczynska J; Wasik M; Lasek W; Jakobisiak M; Golab J
Oncol Rep; 2002; 9(2):427-31. PubMed ID: 11836621
[TBL] [Abstract][Full Text] [Related]
6. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-γ-dependent response against B16F10-Nex2 melanoma.
Marchi LH; Paschoalin T; Travassos LR; Rodrigues EG
Cancer Gene Ther; 2011 Feb; 18(2):110-22. PubMed ID: 20885448
[TBL] [Abstract][Full Text] [Related]
8. Endogenous accumulation of IFN-gamma in IFN-gamma-R(-/-) mice increases resistance to B16F10-Nex2 murine melanoma: a model for direct IFN-gamma anti-tumor cytotoxicity in vitro and in vivo.
Rodrigues EG; Garofalo AS; Travassos LR
Cytokines Cell Mol Ther; 2002; 7(3):107-16. PubMed ID: 12850810
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells.
Wu B; Shen RN; Wang WX; Broxmeyer HE; Lu L
Stem Cells; 1993 Sep; 11(5):412-21. PubMed ID: 8241952
[TBL] [Abstract][Full Text] [Related]
10. Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice.
Dabrowska A; Giermasz A; Marczak M; Gołab J; Jakóbisiak M
Anticancer Res; 2000; 20(1A):391-4. PubMed ID: 10769685
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X
Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621
[TBL] [Abstract][Full Text] [Related]
12. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18.
Lauwerys BR; Renauld JC; Houssiau FA
Cytokine; 1999 Nov; 11(11):822-30. PubMed ID: 10547269
[TBL] [Abstract][Full Text] [Related]
13. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
Lala PK; Parhar RS
Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity.
Ju DW; Yang Y; Tao Q; Song WG; He L; Chen G; Gu S; Ting CC; Cao X
Gene Ther; 2000 Oct; 7(19):1672-9. PubMed ID: 11083476
[TBL] [Abstract][Full Text] [Related]
15. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
Wang D; Li Y; Yu D; Song SS; Kandimalla ER; Agrawal S
Int J Oncol; 2004 Apr; 24(4):901-8. PubMed ID: 15010828
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
[TBL] [Abstract][Full Text] [Related]
17. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
[TBL] [Abstract][Full Text] [Related]
18. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma.
Kircheis R; Küpcü Z; Wallner G; Wagner E
Cytokines Cell Mol Ther; 1998 Jun; 4(2):95-103. PubMed ID: 9681248
[TBL] [Abstract][Full Text] [Related]
19. Role of the endogenous production of interleukin 12 in immunotherapy.
Harada M; Tamada K; Abe K; Yasumoto K; Kimura G; Nomoto K
Cancer Res; 1998 Jul; 58(14):3073-7. PubMed ID: 9679973
[TBL] [Abstract][Full Text] [Related]
20. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.
Guo J; Wang B; Zhang M; Chen T; Yu Y; Regulier E; Homann HE; Qin Z; Ju DW; Cao X
Gene Ther; 2002 Jun; 9(12):793-803. PubMed ID: 12040461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
